Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.51 |
| ▸ | ABL1 | P00519 | 8/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | KIF5B | P33176 | 1/20 | 0.42 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471042 | 0.94 | RET (0.49) | SRCABL1MKNK2BRAFEGFR | |
| SCHEMBL21470715 | 0.92 | KIT (0.45) | SRCABL1BRAFEGFRCDK1 | |
| SCHEMBL21471038 | 0.92 | KIT (0.47) | SRCABL1BRAFEGFRCDK1 | |
| SCHEMBL21470840 | 0.92 | SRC (0.40) | SRCABL1MKNK2BRAFEGFR | |
| SCHEMBL21470719 | 0.89 | HCK (0.46) | SRCABL1MKNK2CSF1RKIT | |
| SCHEMBL21470839 | 0.88 | KIT (0.43) | SRCABL1BRAFEGFRCDK2 | |
| SCHEMBL21470891 | 0.88 | SRC (0.46) | SRCABL1BRAFEGFRCDK1 | |
| SCHEMBL21470892 | 0.87 | FGFR4 (0.47) | SRCABL1BRAFEGFRCDK1 | |
| SCHEMBL21471036 | 0.85 | KIT (0.42) | ABL1MKNK2CSF1RKITBCR | |
| SCHEMBL21470533 | 0.84 | KIT (0.44) | SRCABL1CSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | SRC 1670/4885ABL1 551/4885MKNK2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.